Serum 90K/Mac-2 Binding Protein (Mac-2BP) as a Response Predictor to Peginterferon and Ribavirin Combined Treatment in Hcv Chronic Patients

REFERENCES

• B. Franceschini, C. Russo, N. Dioguardi, and F. Grizzi. 2007. Increased liver mast cell recruitment in patients with chronic C virus-related hepatitis and histologically documented steatosis. J. Vir. Hepat. 14 (8):549–555.
   PubMedGoogle Scholar
• M. Deutsch, E.K. Manesis, E. Hadziyannis, D. Vaasilopoulos, and A.J. Archimandritis. 2007. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b. Scand. J. Gastroenterol. 42 (3):408–409.
   PubMedGoogle Scholar
• T. Suzuki, H. Aizaki, K. Murakami, I. Shoji, and T. Wakita. 2007. Molecular biology of hepatitis C virus. J. Gastroenterology 42 (6):411–423.
   PubMedGoogle Scholar
• H.L. Chan, H. Ren, W.C. Chow, and T. Wee. 2007. Interferon beta-1a Hepatitis C Study Group. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology 46 (2):315–323.
   PubMedGoogle Scholar
• J.G. McHutchison, and T. Poinard. 1999. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.. Seminar Liver Dis. 19 (Suppl 1):57–65.
   PubMedGoogle Scholar
• G.L. Davis, and J.Y. Lau. 1997. Factor predictive of a beneficial response to therapy of hepatitis C.. Hepatology 26 (Suppl 1):122S–127S.
   Google Scholar
• E. Barnes, G. Webster, S. Whalley, and G. Dusheiko. Predictors of a favorable response to alpha interferon therapy for hepatitis C. In: E.B. Keefe Editor. Clinics in Liver Disease. Philadephia: W.B. Saunders, 1999, 775–791.
   Google Scholar
• M. Cornberg, K. Deterding, and M.P. Manns. 2006. Present and future therapy for hepatitis C virus. Expert. Rev. Infect. Ther. 4 (5):781–793.
   PubMedGoogle Scholar
• J.J. Feld, S. Nanda, Y. Huang, W. Chen, M. Cam, S.N. Pusek, L.M. Schweigler, D. Theodore, S.L. Zacks, T.J. Liang, and M.W. Fried. 2007. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46 (5):1548–1563.
   PubMedGoogle Scholar
• M. Persico, M. Capasso, E. Persico, M. Svelto, R. Russo, D. Spano, L. Crocè, V. La Mura, F. Moschella, F. Masutti, R. Torella, C. Tiribelli, and A. Iolascon. 2007. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 46 (4):1009–1015.
   PubMedGoogle Scholar
• A.R. Zekri, H.A. Haleem, G.E. Esmat, A.A. Bahnassy, H.M. El-Din, M.M. Hafez, A.F. Sharaby, H. Sharaf, and M.S. Zakaria. 2007. Immunomodulators, sFas and Fas-l AS potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.. J. Viral. Hepat. 14 (7):468–477.
   PubMedGoogle Scholar
• T.M. Chen, P.T. Huang, M.H. Tsai, C.C. Lin, K.S. Ho, C.P. Siauw, P.L. Chao, and J.N. Tung. 2007. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J. Gastroenterol. Hepatol. 22 (5):669–675.
   PubMedGoogle Scholar
• S. Iacobelli, E. Arno, A. D'Orazio, and G. Coletti. 1986. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 46 (6):3005–3010.
   PubMed Web of Science ®Google Scholar
• K. Koths, E. Taylor, R. Halembeck, C. Casipit, and A. Wang. 1993. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J. Biol. Chem. 268 (19):14245–14249.
   PubMedGoogle Scholar
• A. Ullrich, I. Sures, M. D'Egidio, B. Jallal, T.J. Powell, R. Herbst, A. Dreps, M. Azam, M. Rubinstein, C. Natoli, L.K. Shawver, J. Schlessinger, and S. Iacobelli. 1994. The secreted tumor-associated antigen 90K is a potent immune stimulator. J. Biol. Chem. 269 (28):18401–18407.
   PubMed Web of Science ®Google Scholar
• S. Iacobelli, C. Natoli, M. D'Egidio, E. Tamburini, A. Antinori, and L. Ortona. 1991. Lipoprotein 90K in human immunodeficiency virus-infected patients: A further serologic marker of progression. J. Infect. Dis. 164 (4):819.
   PubMedGoogle Scholar
• N.C. Briggs, C. Natoli, N. Tinari, M. D'Egidio, J.J. Goedert, and S. Iacobelli. 1993. A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. AIDS Res. Hum. Retroviruses 9 (9):811–816.
   PubMedGoogle Scholar
• M. Artini, C. Natoli, N. Tinari, A. Costanzo, D. Angelucci, M. D'Egidio, M. Levrero, and S. Iacobelli. 1996. Elevated serum levels of 90K/Mac-2BP predict unresponsiveness to α-interferon therapy in chronic hepatitis patients. J. Hepatol. 25 (2):212–217.
   PubMedGoogle Scholar
• P.A. Iacovazzi, A. Trisolini, D. Barletta, S. Elba, O.G. Manghisi, and M. Correale. 2001. Serum 90K/Mac-2BP glycoprotein in patients with liver cirrhosis and hepatocelluar carcinoma: A comparison with α-fetoprotein. Clin. Chem. Lab. Med. 39 (10):961–965.
   PubMed Web of Science ®Google Scholar
• A. Rea, G. Palmieri, N. Tinari, C. Natoli, P. Tagliaferri, A. Morabito, and et al 1994. 90K a serum marker of poor prognosis in non Hodgkin's lymphoma patients. Oncol. Rep. 1:723–725.
   PubMedGoogle Scholar
• N. Gentiloni, P. Caradonna, G. Costamagna, N. D'Ostilio, V. Perri, M. Mutignani, and et al 1995. Pancreatic juice 90K and serum Ca 19.9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. Am. J. Gastroenterol. 90 (7):1069–1072.
   PubMedGoogle Scholar
• P.L. Almasio, V. Di Marco, C. Bonura, P. Fuschi, C. Camma, O. Lo Iacono, M. Artini, C. Natoli, R. Di Stefano, M. Levrero, and A. Craxi. 1999. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. Dig. Dis. Sci. 44 (5):1013–1019.
   PubMedGoogle Scholar
• M. Correale, V. Giannuzzi, P.A. Iacovazzi, M.A. Valenza, S. Lanzillotta, I. Abbate, M. Quaranta, M.L. Caruso, S. Elba, and O.G. Manghisi. 1999. Serum 90K/Mac-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Res. 19 (4C):3469–3472.
   PubMedGoogle Scholar
• P.A. Iacovazzi, V. Guerra, S. Elba, F. Sportelli, O.G. Manghisi, and M. Correale. 2003. Are 90K/Mac-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results. Int. J. Biol. Markers. 18 (3):192–196.
   Web of Science ®Google Scholar
• A.M. Valentini, P.A. Iacovazzi, M. Correale, M. Pirrelli, R. Armentano, S. Iacobelli, N. Tinari, I. Iurisci, and M.L. Caruso. 2005. Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies. Med. Chem. 1 (2):185–189.
   PubMedGoogle Scholar
• B. Fornarini, C. D'Ambrosio, C. Natoli, N. Tinari, V. Silingardi, and S. Iacobelli. 2000. Adhesion to 90K (Mac-2BP) as a mechanism for lymphoma drug resistance in vivo. Blood. 96 (9):3282–3285.
   PubMedGoogle Scholar
• M.L. Shiffman, F. Suter, B.R. Bacon, D. Nelson, H. Harley, R. Solà, S.D. Shafran, K. Barange, A. Lin, A. Soman, S. Zeusem, and ACCELERATE Investigators. 2007. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.. N. Engl. J. Med. 357 (2):124–134.
   PubMed Web of Science ®Google Scholar
• T. Poynard, J. McHutchison, Z. Goodman, M.H. Ling, and J. Albrect. 2000. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 31 (1):211–218.
   PubMedGoogle Scholar
• T. Berg, C. Sarrazin, E. Herrmann, H. Hinrichsen, T. Gerlach, R. Zachoval, B. Widenmann, U. Hopf, and S. Zeuzem. 2003. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology. 37 (3):600–609.
   PubMedGoogle Scholar
• G. Taliani, G. Gemignani, C. Ferrari, A. Aceti, D. Brtolozzi, P.L. Blanc, M. Capanni, F. Esperti, P. Forte, V. Guadagnino, and et al 2006. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology. 130 (4):1098–1106.
   PubMedGoogle Scholar
• J.F. Bergmann, J.M. Vrolijk, P. van der Scgaar, B. Vroon, B. van Hoek, A. van der Sluys Veer, R.A. de Vries, E. Verhey, and B.E. Hansen. 2007. et al γ-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-α-2b in chronic hepatitis C non-responders. Liver Int. 27 (9):1217–1225.
   PubMedGoogle Scholar
• G. Taliani, M.C. Badolato, G. Nigro, M. Biasin, V. Boddi, C. Pasquazzi, and M. Clerici. 2002. Serum concentration of γGT is a surrogate marker of hepatic TNF- α mRNA expression in chronic hepatitis C.. Clin. Immunol. 105 (3):279–285.
   PubMedGoogle Scholar
• H. Miyatake, T. Kanto, M. Inoue, M. Sakakibara, A. Kaimori, T. Yakushijin, I. Itose, M. Miyazaki, N. Kuzushita, N. Hiramatsu, T. Takeara, A. Kasahara, and N. Hayashi. 2007. Impaired ability of interferon-alfa-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection. J. Viral. Hepat. 14 (6):404–412.
   PubMedGoogle Scholar
• R. Amaraa, H. Mareckova, P. Urbanek, and T. Fucikova. 2003. Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C.. J. Gastroenterol. 38 (3):254–259.
   PubMedGoogle Scholar
• R.T. Marinho, R. Pinto, M.L. Santos, I.V. Lobos, and M.C. Moura. 2004. Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C.. J. Viral. Hepat. 11 (3):206–216.
   PubMedGoogle Scholar
• E. Jirillo. Hepatitis C virus disease. In: Immunobiology and Clinical Applications. New York: Springer, 2007, 1–306.
   Google Scholar
• N. Semmo, and P. Klenerman. 2007. CD4+ T cell responses in hepatitis C virus infection. World J. Gastroenterol. 13 (36):4831–4838.
   PubMedGoogle Scholar
• E. Billerbeck, T. Bottler, and R. Thimme. 2007. Regulatory T cells in viral hepatitis. World J. Gastroenterol. 13 (36):4858–4864.
   PubMedGoogle Scholar
• B. Jallal, J. Powell, J. Zachwieja, C. Brakebusch, L. Germain, J. Jacobs, S. Iaco belli, and A. Ullrich. 1995. Suppression of tumor growth in vivo by local and systemic 90K levels increase. Cancer Res. 55 (15):3223–3227.
   PubMedGoogle Scholar
• B. Yu, and S.D. Wright. 1995. LPS-dependent interaction of Mac-2-binding protein with immobilized CD14. J. Inflamm 45 (2):115–125.
   PubMedGoogle Scholar
• C. Brakebusch, I. Sures, B. Jallal, K. Mossie, O. Fusco, S. Iacobelli, and A. Ullrich. 1999. Isolation and functional characterization of the human 90K promoter. Genomics. 57 (2):268–278.
   PubMedGoogle Scholar
• T.J. Powell, R. Schreck, M. McCall, T. Hui, A. Rice, H. App, M. Azam, A. Ullrich, and L.K. Shawever. 1995. A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J. Immunother. Emphasis Tumor. Immunol. 17 (4):209–21.
   PubMedGoogle Scholar
• S. Iacobelli, G. Scambia, C. Natoli, P.B. Panici, G. Baiocchi, L. Perrone, and S. Mancuso. 1988. Recombinant human leukocyte interferon-alpha 2b stimulates the synthesis and release of a 90K tumor-associated antigen in human breast cancer cells. Int. J. Cancer. 42 (2):182–184.
   PubMedGoogle Scholar
• C. Natoli, C. Garufi, N. Tinari, M. D'Egidio, L.A. Gaspari, R. Visini, and S. Iacobelli. 1993. Dynamic test with recombinant interferon-alpha 2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. Br. J. Cancer. 67 (3):564–567.
   PubMedGoogle Scholar
• G. Scambia, B.P. Panici, G. Baiocchi, A. Gallo, G. Laurelli, S. Iacobelli, and S. Mancuso. 1991. Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer. A preliminary report. Cancer. 68 (12):2582–2585.
   Google Scholar
• L. Amati, L. Caradonna, T. Magrone, M.L. Mastronardi, R. Cuppone, R. Cozzolongo, O.G. Manghisi, D. Caccavo, A. Amoroso, and E. Jirillo. 2002. Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirin. Curr. Pharm. Des. 8 (11):981–993.
   PubMedGoogle Scholar
• A. Grassadonia, N. Tinari, B. Fiorentino, M. Nakazato, H.K. Chung, C. Giuliani, G. Napolitano, S. Iacobelli, T.K. Howcroft, D.S. Singer, and L.D. Kohn. 2007. Consorzio Interuniversitario Nazionale per la Bioncologia. Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. Endocrinology 148 (7):3507–3517.
   PubMedGoogle Scholar
• S. Corre, and M.D. Galibert. 2005. Upstream stimulating factors: Highly versatile stress-responsive transcription factors. Pigment. Cell Res. 18 (5):337–348.
   PubMedGoogle Scholar